ArticleJournal of neurology2026
Long-term neurological outcome after hematopoietic stem cell transplant in juvenile Krabbe disease.
Article in Journal of neurology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Erratum issued
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundGloboid cell leukodystrophy (GLD) is a progressive neurodegenerative disease caused by galactocerebrosidase deficiency. Juvenile phenotypes-onset between ages 3 and 16-account for up to 25% of cases. Hematopoietic stem cell transplantation (HSCT) is the only available treatment, yet only eight juvenile-onset cases treated with HSCT have been reported, with heterogeneously collected data. We aim to comprehensively evaluate long-term neurological outcomes post-HSCT in juvenile GLD.
methodsWe conducted a retrospective study of all juvenile GLD patients treated with HSCT and followed at our Institution. We assessed survival, neurological status, disability (modified Rankin Scale), cognitive outcomes, GALC activity, serial MRIs (Loes score), evoked potentials (internal scoring system), and nerve conduction studies at pre-HSCT, first post-HSCT visit, and last follow-up.
resultsSix biochemically and genetically confirmed juvenile GLD cases were included. Four were symptomatic at diagnosis; two were pre-symptomatic. All survived to last follow-up (range 9 years, 2 months-19 years, and 8 months). Four achieved near-normal cognitive, motor, and functional status. Two symptomatic patients-with extensive pre-HSCT white matter disease and specific pre-HSCT clinical features (epilepsy and cognitive impairment)-had suboptimal outcomes. Loes scores stabilized/improved in four patients; GALC enzyme activity normalized in all. Electrophysiological measures mostly remained stable.
conclusionsHSCT significantly impacts the natural history of juvenile GLD, resulting in largely optimal long-term outcomes, preserved quality of life, and minimal disability. Standardized pre-transplant assessments are critical. High pre-HSCT Loes scores, epilepsy, and cognitive impairment could be prognostic indicators, highlighting the importance of early intervention based on comprehensive instrumental evaluations.
Indexed as
Identifiers
41604001What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.